Author
Peter K. Henke
Other affiliations: Veterans Health Administration
Bio: Peter K. Henke is an academic researcher from University of Michigan. The author has contributed to research in topics: Venous thrombosis & Thrombosis. The author has an hindex of 61, co-authored 340 publications receiving 12171 citations. Previous affiliations of Peter K. Henke include Veterans Health Administration.
Topics: Venous thrombosis, Thrombosis, Thrombus, Inferior vena cava, Deep vein
Papers published on a yearly basis
Papers
More filters
Tufts University1, University of Alabama at Birmingham2, University of Michigan3, Indiana University4, Lund University5, University of Illinois at Chicago6, Uniformed Services University of the Health Sciences7, Mayo Clinic8, University of North Carolina at Chapel Hill9, Oregon Health & Science University10, Medical University of Vienna11, University of Texas Health Science Center at San Antonio12, Harvard University13, Duke University14
TL;DR: Thomas F. O'Donnell, MD, Marc A. Passman and Peter K. Gloviczki as mentioned in this paper, MD, PhD, Bo G. Eklof et al.
497 citations
TL;DR: The retrospective risk scoring method is valid and supports use of individual patient assessment of risk for VTE within 30 days after surgery, and significant correlation between the probability of VTE and lack of adherence to prophylaxis guidelines is demonstrated.
Abstract: Objectives:Validate a retrospective venous thromboembolism (VTE) risk scoring method, which was developed at the University of Michigan Health System and based on the Caprini risk assessment model, and assess the confounding effects of VTE prophylaxis.Background:Assessing patients for risk of VTE is
497 citations
Lutheran Medical Center1, Harvard University2, University of Michigan3, University of Washington4, University of Massachusetts Amherst5, Geisinger Health System6, Brown University7, Veterans Health Administration8, University of North Carolina at Chapel Hill9, Baylor College of Medicine10, Mayo Clinic11
TL;DR: These guidelines have addressed five key areas in the care of DFUs, but they do not cover all the aspects of this complex condition and as future evidence accumulates, they plan to update their recommendations accordingly.
368 citations
TL;DR: Given the relative high perioperative mortality associated with TAAA repair, regionalization of care to high-volume providers with consistently lower postoperative mortality deserves consideration by patients, physicians, and health care planners.
367 citations
TL;DR: The unique role of inflammation to the venous thrombotic process is emphasized as well as the potential role of abnormalities of fibrinolytic mechanisms to the thromBotic process.
Abstract: Venous thromboembolism is a significant health care problem in the US. In this review, the unique role of inflammation to the venous thrombotic process is emphasized as well as the potential role of abnormalities of fibrinolytic mechanisms to the thrombotic process. Inflammation influences not only thrombogenesis but also thrombus resolution and vein wall remodeling, and these interactions are also discussed. Knowledge of molecular and immunologic mechanisms for venous thrombosis and its resolution should allow for the future development of targeted therapies.
322 citations
Cited by
More filters
TL;DR: The goals of this new consensus are to provide an abbreviated document to focus on key aspects of diagnosis and management, and to update the information based on new publications and the newer guidelines, but not to add an extensive list of references.
7,099 citations
TL;DR: Strong recommendations apply to most patients, whereas weak recommendations are sensitive to differences among patients, including their preferences.
5,924 citations
01 Jan 2020
TL;DR: Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.
Abstract: Summary Background Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described. Methods In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings 191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients). Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03–1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61–12·23; p Interpretation The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future. Funding Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development.
4,408 citations
TL;DR: This article discusses the prevention of venous thromboembolism (VTE) and is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
3,944 citations
TL;DR: The ACC and AHA have collaborated with the National Heart, Lung, and Blood Institute and stakeholder and professional organizations to develop guidelines, standards, and policies that promote optimal patient care and cardiovascular health.
Abstract: Preamble and Transition to ACC/AHA Guidelines to Reduce Cardiovascular Risk S50
The goals of the American College of Cardiology (ACC) and the American Heart Association (AHA) are to prevent cardiovascular diseases (CVD); improve the management of people who have these diseases through professional education and research; and develop guidelines, standards, and policies that promote optimal patient care and cardiovascular health. Toward these objectives, the ACC and AHA have collaborated with the National Heart, Lung, and Blood Institute (NHLBI) and stakeholder and professional organizations to develop …
3,524 citations